UNIVERSITÉ DE LILLE

FACULTÉ DE MÉDECINE HENRI WAREMBOURG

Année : 2020

THÈSE POUR LE DIPLÔME D'ÉTAT
DE DOCTEUR EN MÉDECINE

Facteurs prédictifs de pathologie Alzheimer, inférée d'après le profil des biomarqueurs du liquide cérébro-spinal, chez des patients porteurs de troubles neurocognitifs vasculaires au centre mémoire de Lille.

Présentée et soutenue publiquement le 23 septembre 2020 à 16h00

Au Pôle Recherche

Par Aymeric WITTWER

_____

JURY

Présidente:

    Madame le Professeur Florence PASQUIER

Assesseurs :

    Madame le Professeur Charlotte CORDONNIER

    Monsieur le Docteur Gregory KUCHCINSKI

Directrice de thèse :

Madame le Docteur Marie-Anne MACKOWIAK-CORDOLIANI

_____

La Faculté n'entend donner aucune approbation aux opinions émises dans les thèses : celles-ci sont propres à leurs auteurs.

Table of contents

GLOSSARY

AD: Alzheimer's disease

CAA: Cerebral amyloid angiopathy

CADASIL: Cerebral Autosomal Dominant Arteriopathy with Subcortical infarcts and Leukoencephalopathy

CMB: Cerebral microbleed

CSF: Cerebrospinal fluid

CSS: Cortical superficial siderosis

DRS: Dementia rating scale

DWH: Deep white matter hyperintensities

FAB: Frontal assessment battery

ICH: Intracerebral Hemorrhage

MMSE: Mini Mental State Examination

MRI: Magnetic Resonance Imagery

PVH: Periventricular hyperintensities

RL-RI 16: Rappel libre-rappel indicé 16 items

VaD: Vascular dementia

VAT: Visual association test

VCI: Vascular cognitive impairment

ABSTRACT

Background: Vascular cognitive impairment (VCI) represents the second cause of dementia after Alzheimer's Disease (AD). These two pathologies are frequently associated, defining mixed dementias (MD). In France, in 2020, the clinician currently relies on the cerebro-spinal fluid (CSF) biomarkers to prove *in vivo* the pathological process of AD in clinical routine. However, lumbar puncture is not always easily available and may be contra-indicated by frequent ongoing antithombotic treatments in those population. The aim of our study was to identify, in patients diagnosed with VCI, which clinical, neuropsychological and radiological features are correlated to associated AD lesions, inferred from the CSF biomarkers profile.

Methods: In a monocentric cohort from the Lille memory clinic, we included patients with last diagnosis retained of MD or VCI, and whose the CSF biomarkers were available. Then we defined 2 profiles of CSF based on the analysis of biomarkers: VCI-CSF and MD-CSF. We used bivariate analysis to compare clinical, neuropsychological, and MRI features (with a rigorous analysis of cerebrovascular diseases biomarkers and atrophy pattern) between patients with VCI-CSF and MD-CSF.

Results: 76 patients have been included, 45 (59%) with MD-CSF profile et 31 (41%) with VCI-CSF. Those with VCI-CSF presented lower Frontal Assessment Battery (FAB) raw scores ($p = 0.003$) and had a higher proportion of pathologic scores at the Dementia Rating Scale (DRS) conceptualization subscale ($p = 0.0091$). The distribution of cerebrovascular disorders markers did not differ between the two groups. Patients with VCI-CSF were likely to harbor global cerebral atrophy ($p = 0.01$) whereas those with MD-CSF presented a significantly right-sided parietal atrophy ($p = 0.04$).

Conclusion: Our results suggest that patients with VCI present worse dysexcutive impairment than those with MD, and that the pattern of atrophy differs between the two pathologies. Prospective cohorts with standardized batteries of test and MRI reading plan are mandatory to answer this major diagnostic and therapeutic issue and maybe establish clinico-radiological scores predictive of the CSF profile when the sample is not possible.

INTRODUCTION

Because the risk of dementia increases with age, as life expectancy has improved, dementia has become an important public health problem and a major social and economic burden. According to current estimates, almost 36 million people are having dementia worldwide, and this number is expected to reach 66 million by 2030 and 115 million by 2050 [1].

Vascular dementia (VaD) and vascular cognitive impairment (VCI) result from cerebrovascular disorders responsible for brain parenchymal lesions determining an impairment of cerebral functions. Vascular dementia represents the leading cause of dementia after Alzheimer' disease (AD), accounting for about 15-20% of dementias in developed countries. The prevalence of VaD in the European population older than 65 years is estimated at 1.6%, versus 4.4% for AD. The prevalence of both VaD and AD rises exponentially with age, with the risk of VaD doubling every 5.3 years [2]. The prevalence of VCI, which includes milder forms of cognitive impairment who do not met criteria of dementia (that is, without loss of functional independency), have been estimated by the Canadian Study of Health Aging at 5% in general population over 65 years [3].

Dementia related to cerebrovascular disorders has been first described by Mc Menemey in the early 1960's, who labeled it "atherosclerotic dementia", as it was originally conceived as an arteriosclerotic disorder arising from diffuse low cerebral perfusion [4].

Following the progresses of neuropathology studies, multiple large and small vessels lesions, parenchymal ischemic as well as hemorrhagic patterns have been

highlighted. The term **"vascular cognitive disorders"** encompasses multiple clinical and pathological entities:

> **Post stroke dementia or post stroke cognitive impairment** refers to the cognitive disorders which are highlighted after stroke. Prevalence of post-stroke dementia approaches 15% to 30% of stroke survivors, and rises with age, and stroke recurrences [5, 6, 7]

> **Multiple infarct dementia:** the occurrence of multiple small or large infarcts has long been recognized as a cause of dementia. Larger infarct volumes and a higher number of territorial infarcts are associated with worse cognitive performances and higher risks of dementia. However, there is no definite threshold for an overall volume of damaged parenchyma required for the occurrence of VCI or VaD [8, 9, 10] .

> **Strategic infarct dementia:** More important than the volume of the infarct is its location. A single small infarct may cause severe cognitive deficits when located in an eloquent functional region, (*ie* a lacunar infarct in the left thalamus may lead to severe verbal episodic memory impairment). Results of clinical-pathological studies have been summarized by Jellinger [8, 9], who proposed in his neuropathological classification to define a strategic lesion when involving the thalamus, the caudate nucleus, the mesial temporal lobe, angular or cingulated gyri.

> **Subcortical vascular encephalopathy,** sometimes referred as Biswanger's disease, which associates extensive and confluent white matter hyperintensities (WMH) and, in variable levels, other biomarkers of small vessel disease such as lacunar infarcts, cerebral micro infarcts, cerebral micro bleeds (CMB) or enlargement of perivascular spaces (EPVS). The nature and

the topography of those biomarkers may directly reflect the underlying microangiopathy [8, 9,10].

The two most frequent **sporadic microangiopathies** are:

- The deep perforating vasculopathy, in which patients are more likely to harbor lacunar infarcts and EPVS in the deep white matter and basal ganglias [11]

- And cerebral amyloid angiopathy (CAA), characterized by extensive WMH with a posterior predominance, EPVS in subcortical regions [11, 12] strictly cortico-subcortical CMB and /or the presence of cortical superficial siderosis (CSS). [11]

Other genetic microangiopathies, such as CADASIL (Cerebral Autosomal Dominant Arteriopathy with Subcortical Infarcts and Leukoencephalopathy) may be considered as the prototype of a subcortical vascular impairment [13].
The 3 pathological patterns described above are schematized in Figure n°1.

➢ **Hemorrhagic dementia:** Giving the high mortality rates at the acute phase of Intracerebral Hemorrhage (ICH), data were scarce about the occurrence of dementia in ICH survivors. Moulin & *al* [14] in 2016 first described, in a large monocentric cohort of ICH survivors without pre-existing dementia, a new onset dementia incidence of 14,2 and 28.3% at one year and 4 years of follow-up respectively. The occurrence of dementia was 2 times higher in patients who presented a lobar hemorrhage compared to those presenting with a deep hemorrhage, suggesting a role of CAA in cognitive decline.

Figure n°1: Mechanisms of VCI (extracted from *Jellinger, 2013* [9])

CN indicates caudate nucleus; Amy amygdala; CA1, Ammon's horn sector CA1; Cing, cingulate gyrus; ER, entorhinal cortex, F, frontal neocortex; Hypoth, hypothalamus; NBM, basal nucleus; ST , striatum; Thal, thalamus; T, temporal neocortex; Thal, thalamus

VCI is a broad concept that covers mixed pathologies regardless of underlying mechanisms and irrespective of the occurrence of stroke symptoms. Thus, the diagnosis has highly benefited from the progress of cerebral imaging, particularly in patients with no clinical history of stroke.

The first diagnostic criteria edited by the NINDS-AIDRA report (National Institute of Neurological Disorders and Stroke and the Association Internationale pour la Recherche et l'Enseignement en Neurosciences) [15] in 1993 defined VaD when the following requirements were met: (1) the patient must be demented; (2) there must be evidence of cerebrovascular disease (history, clinical examination, or brain imaging) and (3) the two disorders must be reasonably related.

However, these guidelines only considered demented patients (thus excluding those with mild cognitive impairment) and required a temporal relation between the

symptoms onset and the occurrence of a stroke, or, in patients with subcortical vascular dementia, a stepwise progression of cognitive deficits.

Hachinski and *al* [16], for the NINDS and the Canadian Stroke Network, were the first to include mildest forms of cognitive impairment, and to standardize clinical, neuropsychological and MRI patterns of VCI. The most recent diagnostic criteria developed by Sachdev and *al* for the VASCog statement, published in 2014 [17], no longer require the presence of memory impairment, a typical feature of AD. Hence, neuropsychological testing should cover at least 4 different cognitive domains. A diagnosis of VaD requires deficits in at least 2 domains, whereas deficits in a single domain are sufficient to diagnose vascular mild cognitive impairment.

The heterogeneity of pathology substratum in VCI suggests that the cognitive deficits will vary according to the brain regions affected and the type of onset of the lesions. For example, a patient who presented a so-called strategic infarction in the left posterior cerebral artery may brutally present deficits in verbal memory and speech disturbances, whereas a patient who harbors extensive white matter hyperintensities and multiple lacunes will be more likely to present an isolated dysexecutive and frontal profile with a progressive worsening.

Despite these heterogeneous presentations, there is substantial evidence to suggest that frontal-executive functions disturbances, rather than memory, is often the most specific feature of VCI and helps to differentiate VCI from AD, particularly in patients presenting with mild cognitive impairment [18, 19, 20].

As vascular lesions may disrupt thalamocortical, striatocortical, and prefrontal-basal ganglia pathways, and thus affect cortical and limbic brain circuits, VCI is often associated with behavioral and emotional disturbances [21]. As these neuropsychiatric

features are not specific to vascular etiology, they are not considered as diagnostic items.

Moreover, the classic description of multi-infarct dementia and its acute stepwise or fluctuating decline in cognition is no longer retained in the VASCog statement, given that many patients with VCI do not harbor this clinical picture and show a gradual onset with slow progression, generally associated with small vessel disease.

A challenging issue for clinicians is to differentiate VCI from AD as the natural history and prognosis, as well as symptomatic treatments, are different.

However, several considerations make this distinction difficult:

> VCI and AD share the same risk factors: age, hypertension (particularly in mid-life) [22], diabetes mellitus [23], atrial fibrillation [24], carry of the ApoE4 allele [25].

> Vascular lesions such as "silent" brain infarctions, WMH, lacunes and CMB are common in the general population [26, 27, 28] and may not be considered straightaway in cause of a cognitive deficit.

> A large part (about one third) of post-stroke dementia are associated with underlying unknown or misdiagnosed AD ([5, 6, 29]).

> CAA, a common microangiopathy responsible for VCI in the elderly, found to be associated up to 96 % of subjects presenting AD pathological lesions [30].

Moreover, the two processes (vascular and degenerative) are frequently associated in the elderly, defining mixed dementia (MD). In clinical pathological

studies, the proportion of MD cases clinically misclassified as VaD was up to 18 to 54%, particularly in the very old [31, 32, 33].

Then, how to differentiate VCI from MD in clinical practice?

Considering neuropsychological profiles, Bruandet and *al* [34] showed that patients with MD tended to be significantly older than those with VCI. The baseline scores of two global cognitive evaluations (Mini Mental State Examination and Dementia Rating Scale) were highest for VCI compared with MD. Cognitive decline during follow-up was also slowest for isolated VCI. Moreover, in a large autopsy cohort from the Rush Memory and Aging Project [33], after accounting for age, patients with mixed pathology were almost three times more likely to exhibit dementia (rather than no cognitive complain or mild cognitive impairment) compared to those with one pathologic diagnosis, suggesting a cumulative effect of the different lesions.

Another way to distinguish MD from isolated VCI is to look for typical radiological patterns of AD.

➢ AD is typically associated with early **medial temporal lobe atrophy (MTA).** The presence of MTA on MR imaging improves the discrimination of AD from healthy controls and predicts progression to dementia in patients with mild cognitive impairment (MCI) [35, 36]. However, MTA is not a specific pattern and is also present in other causes of dementias, particularly frontotemporal lobar degeneration, vascular cognitive impairment, major psychiatric issues such as bipolar disorder [37].

➢ Occasionally, AD patients present with a striking **posterior atrophy pattern**, more generally with atrophy of the posterior cingulate gyrus, precuneus and

parietal lobes. Posterior atrophy appears to be characteristic of AD and may help in the distinction from frontotemporal lobar degeneration [37, 38].

➢ **¹⁸F-fluorodeoxyglucose (FDG) PET**: a scan is suggestive of AD if the pattern of hypometabolism is temporoparietal and posterior cingulate. In a voxel-based multivariate analysis of 18FDG-PET, a hypometabolism in deep gray nuclei, cerebellum, primary cortex, middle temporal gyrus, and anterior cingulate cortex differentiated subcortical VCI from AD with a complete accuracy [39].

➢ **The amyloid PET** is highly correlated to Aβ neuritis plaques in radiolo-pathological studies [40] but is not available in daily routine in France, because of a lack of reimbursement from healthcare. Thus, it is mostly used in diagnostic and therapeutic trials.

➢ **The TAU PET** is highly correlated to DNF and to the pathologic Braak's staging [41] but does not have marketing authorization in France yet.

The use of CSF biomarkers has strengthened the link between clinical dementia and AD pathology. Currently, cerebrospinal fluid (CSF) biomarkers are commonly used in memory clinics. The typical profile observed in AD consists in a striking diminution of $A\beta_1 42$ level, which is correlated with the accumulation of neuritis plaques and elevation of total Tau (t-Tau) and phosphau Tau (p-Tau) levels, which reflects the neurofibrillary degeneration [42].

The current guidelines of the IGW 2 [43] recommend the presence at least of one amyloid genesis marker, *ie* diminution of $A\beta_1 42$ level, and a taupathy marker (*ie* elevation of t-Tau or p-Tau) to consider the CSF as evocative of AD.

A more recent marker, **the $A\beta_1 42$-$A\beta_1 40$** ratio has been proposed to better reflect the brain amyloid production, and is useful in case of discrepancy of $A\beta_1 42$ and t-Tau or p-Tau levels (typically, a normal $A\beta_1 42$ level with elevated t-Tau or p-Tau levels) [44] .

Therefore, in 2020, due to the non-availability in the common clinical setting of TAU and amyloid PET, French clinicians rely on the CSF biomarkers to prove the AD pathological process and differentiate MD from VCI.

However, in a population of elderly patients with vascular comorbidities, lumbar puncture may be at risk or contra-indicated because of ongoing antithrombotic therapies, such as dual antiplatelet or anticoagulant treatment. Furthermore, the sample may be technically difficult to obtain, or may be refused by the patient. In those cases, when the proof of the pathophysiological process cannot be obtained, how to differentiate patients with VCI from those with MD ?

The aim of our study was to determine in patients diagnosed with VCI, which clinical, neuropsychological and radiological factors were associated with an associated AD pathological process, inferred from the CSF biomarkers. As a second end point, we attempt to establish, based on those items, a clinic-radiological score that may be predictive of the CSF profile.

Given the strong correlation between AD and CAA, we focused especially on the analysis of the radiological biomarkers of ICH and cerebral small diseases.

METHODS

Our population was extracted from a large monocentric cohort from the Lille University Hospital memory clinic. In a commune database, were pooled consecutive patients of the memory clinic classified as AD, VCI or MD, from 2004 to January the 1st, 2020. Patients may have been referred to the memory clinic because of a cognitive complaint (coming from themselves or from their relatives), or referred from another medical unit, especially stroke units for a systematic evaluation following a stroke.

All patients benefited at least of one medical evaluation at the memory clinic. If the long term follow-up was ensured at the memory clinic, patients may have variably undergone the following exams: neuropsychological assessment, cerebral MRI, cerebral scintigraphy or 18 FDG PET, CSF biomarkers analysis.

At every medical evaluation, clinical diagnosis was revised according to the clinical and neuropsychological evolution, CSF and imagery findings and was classified according to the current guidelines as:

➢ **Probable AD** (in the absence of CSF biomarkers) when the patient fulfilled the Mc Kahn criteria for probable AD [45]

➢ **Probable AD post biomarkers** (in the presence of CSF biomarkers) when the patient fulfilled the McKahn criteria for probable AD with evidence of the pathophysiological process [45], or those of the IWG 2 for typical or atypical AD [43].

➢ **Certain AD** when an autosomal dominant mutation in the PSEN1, PSEN2, APP genes was highlighted or when the neuropathology (autopsy) confirmed the diagnosis.

- ➤ **Probable VCI** when the patient fulfilled the current VASCog criteria and in the absence of arguments for an associated AD [17].

- ➤ **Certain VCI** when the neuropathology (autopsy) confirmed the diagnosis.

- ➤ **Probable MD** if the patient met the criteria for probable AD or probable AD post biomarkers and probable VCI. The current guidelines [43, 45] describes etiologically mixed presentations when they meet all core clinical criteria for AD dementia but has evidence of a concomitant cerebrovascular disease, defined by a history of stroke temporally related to the onset or worsening of cognitive impairment; or the presence of multiple or extensive infarcts or severe WMH burden.

- ➤ **Certain mixed dementia** when the neuropathology (autopsy) confirmed the diagnosis.

We used in our study all the data collected in this cohort until the January 1st, 2020.

To be included in our study, all the patients must have fulfilled the following items:

- ➤ Last diagnosis retained: VCI or MD

- ➤ Availability of the CSF biomarkers

- ➤ Availability of a neuropsychological assessment and a 3T cerebral MRI

The three examinations above must have been achieved in a maximum period of two years.

We excluded patients for whom the last retained diagnosis was isolated AD.

⇨ **CSF analysis:**

All CSF analysis were performed at the Lille University Hospital Neurobiology department. The parameters were the levels of t-Tau, p-Tau and $A\beta_1 42$. The techniques and thus the normative values used by the laboratory have changed over the years: since in 2004, the dosages were manually performed with ELISA immunologic techniques. Since September 2010 we used the recipient file SARSTEDT 62.610.201 then the technique of detection was secondarily automatized with acquisition of the *Lumipulse* technique since January 2019.

The cut-offs used by the Lille neurobiology department are summarized in the <u>table n°1.</u>

<u>Table n° 1: Cut-offs for the CSF parameters at the Lille university Hospital neurobiology department</u>

Period	t-Tau (pg/mL)	p-Tau (pg/mL)	$A\beta_1$-42 (pg/mL)	$A\beta_1 42$-$A\beta_1 40$ ratio
Before September the 1st, 2010	< 300 if aged 21 to 50 years < 400 if aged 51 to 70 years < 500 if aged ≥ 71 years	< 50	> 500	> 0. 06
Between September the 1st,2010 to December the 31th, 2018	< 400	< 60	> 700	> 0.06
Since January the 1st, 2019	< 525	< 73	> 615	> 5.6%

In our study, and conformingly to the IGW 2 criteria, we considered a CSF profile as evocative of AD if:

➢ the level of $A\beta_1 42$ was diminished, <u>or</u> if the $A\beta_1 42$-$A\beta_1 40$ ratio was under the cut-off at the time the CSF was sampled

➢ AND if the level of t-Tau and/or p-Tau was/were elevated beyond the cutoff at the time the CSF was sampled

In all other situations, the CSF profile was considered as non-evocative of AD.

By extension, in our study, patients presenting a CSF profile evocative of AD were referred as **MD-CSF patients**, the others were referred as **VCI-CSF patients**.

⇨ **Baseline characteristics**

We collected relevant clinical data that may have an impact on cognitive functions: demographics, vascular risk factors, history of stroke, sleep apnea syndrome, or epilepsy.

Concerning the demographics, the current age at which the CSF fluid sample was performed, the gender, and level of education (assessed by the number of years of education) were reported.

Vascular risk factors were reported. We defined:

➢ Arterial hypertension (HTN) was defined as a blood pressure value > 140/90 mmHg measured at rest on two separate assessments, or current antihypertensive therapy.

➢ Diabetes mellitus (DM) as a fasting blood glucose level > 7 mmol/L on two separate measurements, or a current antidiabetic therapy.

➢ Dyslipidemia as an LDL cholesterol elevation ≥ 1.6 g/L and/or a triglyceride level ≥ 1.5 g/L and/or current of a lipid-lowering treatment.

➢ Obesity as a current body mass index (BMI) ≥ 30 kg/m².

➢ Tobacco intoxication as a current or past tobacco use.

➢ Heavy alcohol intake as a current or past daily alcohol intake ≥ 30 g for men, ≥ 20 g for women.

- Sleep apnea syndrome as an Apnea-Hypopnea Index ≥ 15/hour (thus including the usual definition of moderate and severe sleep apnea syndrome).

Concerning the relevant medical history, we reported:

- Atrial fibrillation (past or current)

- Epilepsy as the presence of a current or past epileptic syndrome or disease

- Peripheral Arterial Disease and ischemic heart disease

- Ischemic stroke and history of probable TIA, regardless of their etiologies

- Spontaneous ICH, *ie,* without traumatic of apparent malformative cause.

⇨ **Neuropsychological assessment**

Firstly, we collected the available scores for three simples scales used in daily routine for cognitive screening:

- The **Mini mental status examination (MMSE) score**, a 30-points scale worldwide used to assess global cognitive efficiency at patient's bedside [46].

- The **Frontal Assessment Battery (FAB),** originally known in French as the *Batterie Rapide d'Efficience Frontale*) [47], a 18-points scale, used for assessing frontal functions, such as lexical fluency and inhibitory control.

- The **test of *5 mots de Dubois*,** which allows a rapid evaluation of verbal memory, and has been validated as accurate to discriminate AD from other dementias. [48]

Secondly, we collected the available scores for three worldwide-used scales, the first for a global cognitive performance assessment, and the two followings evaluated episodic memory on its two facets (verbal and non-verbal).

> The **Mattis dementia rating scale (DRS),** a global scale on 144 points, designed to assess global cognitive efficiency, divided in five sub-scales [49]. The total score, and the scores in the attention, initiation, construction, conceptualization and memory subscales were reported. A score was considered pathologic under the 5th percentile.

> **The French version of 16-items free and Cued Recall procedure (Rappel Libre – Rappel Indicé 16 items/ RL-RI 16)**, developed by Grober and Buschke [50] in 1987, adapted by Van der linden and *al* [51] which ensures semantic processing and coordinates encoding and retrieval has been shown to be very sensitive to an early diagnosis of AD. We used the French normative data developed by Amieva and *al* [52] to assess the performance of each patient. A score was considered pathologic under the 5th percentile. The sensitivity to cueing was described as a percentage, and considered pathologic under the 10th percentile. When the patient was too demented to pass the test, leading to a precipitate abandon, he was considered to have a pathologic sensitivity to cueing.

> The **Visual Association Test (VAT)**, a brief learning task based on imagery mnemonics. The test materials consist of six line drawings of pairs of interacting objects or animals. This test has been validated to distinguish patients with AD from other types of dementia, particularly VaD [53]. A score was considered as pathologic under the 5th percentile.

⇨ **MRI evaluation**:

All patient underwent a cerebral 3T MRI. The protocol must have included at least 3 keys sequences: Fluid Attenuation Inversion Recovery (FLAIR), T2 weighed

gradient echo (GRE) and 3D T1 weighed. Given the retrospective design and differences in protocols of images acquisition, the thickness of the slices and the additional sequences may have varied from a patient to another.

We established a systematic reading plan of the cerebral MRI, following this four-part analysis: report of large vessel infarctions and ICH, analysis and profile of small vessel diseases biomarkers, assessment of strategic lesions, cerebral atrophy pattern. All images were evaluated by a neurologist blinded of the CSF profile.

1. Assessment of large vessel infarct and ICH:

We reported previous cerebral infarctions:

➢ Previous supra-tentorial large vessel infarct, in the anterior cerebral artery (ACA), middle cerebral artery (MCA), posterior cerebral artery (PCA) and anterior Choroidal artery (AChoA) territory, regardless of their deep or superficial topography-

➢ Previous infra-tentorial large vessel infarct, that we divided in two categories: those involving the PICA territory, the other involving other territories of large vessels : antero inferior cerebellar artery (AICA) and cerebellar superior artery (CSA)

Supratentorial ICH were classified as:

➢ lobar when the main bulk of the hemorrhage was centered in the cortical grey matter and/or the underlying subcortical white matter

➢ deep when the main bulk of the hemorrhage was centered in the basal ganglia and the deep white matter (internal and external capsules)

When the ICH was restricted to the cerebellum we classified them according the criteria proposed by Pasi and *al* [54]:

➢ lobar when the main bulk of the hemorrhage was centered in the superficial cerebellar cortex or at the junction of the cortex and the underlying white matter

➢ deep when the main bulk of the hemorrhage was centered in the deep cerebellum, involving deep cerebellar grey nuclei and white matter

2. Assessment of cerebral small vessel diseases biomarkers

CMB, lacunes of presumed vascular origin, WMH were defined on the STRIVE consensus criteria by Wardlaw and *al* [55] (Shown in supplemental material n°1).

Table n° 2: Criteria of classification small vessel diseases biomarkers

Cerebral microbleeds	CMB were classified as: • lobar when located in the cerebral cortex or the grey white junction, the subcortical white matter - and/or the cerebellar cortex • deep when located in the thalamus, basal ganglia, internal and external capsules – and/or the brainstem, the deep cerebellar gray nuclei and white matter • mixed when located in both lobar and deep locations
White matter hyperintensities	White matter hyperintensities were scored according the Fazekas' four-point scale [56] divided in perivascular Hyperintensities (PVH) and Deep White Matter Hyperintensities (DWMH). We considered PVH and DWMH as: absent or mild when the Fazekas' score was 0-1, moderate when 2, severe when 3.
Lacune of presumed vascular origin	The topographic distribution of lacunes was recorded on the example given by Pasi and *al* [57]: • lobar when restricted in centrum semiovale, frontal, parietal,

	insular, temporal, and occipital lobes
	• deep when restricted in thalamus, basal ganglia, internal and external capsule, infratentorial
	• mixed when located in both lobar and deep locations

CSS was defined according the criteria of Charidimou [58] and *al* and considered as focal when involving < 4 sulci, disseminated when involving ≥ 4 sulci

EPVS were not included in this assessment, given that a T2-weighed sequence was not available in most of the patients.

3. Assessment of strategic lesions:

We defined a strategic lesion according to the classification by Jellinger [8] as a cerebral infarction, intracerebral hemorrhage or lacune located or involving the thalamus, the caudate nucleus, the medial temporal lobe, the angular gyrus, the fronto cingulate gyrus. All strategic lesions were reported.

4. Assessment of cerebral atrophy:

The global and focal cerebral atrophy were all assessed on visual radiologic scales reported in Table n°3.

Table n° 3: Criteria of cerebral atrophy in our study

|	
Global cerebral atrophy	The Evan's index measures the ratio between the maximal diameter between frontal horns of lateral ventricles and maximal biparietal diameter on the same slice. Formerly used as a diagnostic criterion for ventriculomegaly in normal pressure hydrocephalus, it has been described has a robust reflect of global cerebral atrophy [59]. A patient is considered to harbor global cerebral atrophy when Evans' Index was > 0.3.
Medial temporal atrophy	The medial temporal atrophy was scored on the Scheltens' score, a five-point scale worldwide used to assess hippocampal atrophy in clinical routine [60]. In our study, the medial temporal atrophy was defined as: absent when the Scheltens' score was 0, moderate when 1-2, severe when 3-4.
Parietal atrophy	We used the four-point scale developed by Koedam & *al* [61] to assess the posterior regions atrophy, particularly the parietal lobes (Shown in supplemental material n°2) The parietal atrophy was considered as absent when the atrophy score was 0, minimal when 1, moderate when 2, severe when 3.

⇨ **Statistical analysis**

The quantitative variables have been described by the mean and the standard deviation (in case of normal distribution) or by the median and the interquartile interval (IQR) in the contrary case. The qualitative variables are presented as numbers and percentages. Patients have been compared in function of their CSF profile as MD-CSF or VCI-CSF. Qualitative variables have been studied by a Chi² test or a Fisher Exact test (when n < 5). A t – test of Student or a Mann-Whitney test was used for quantitative variables. The level of significance was fixed at $p = 0.05$. Statistical analysis were performed thanks to the software SAS institute version 9.4.

RESULTS

The flow chart of our study is represented on <u>figure n°2</u>.

<u>Figure n°2: Flow chart</u>

Our population is composed of 76 patients, of which 45 (59%) with MD-CSF

profile, and 31 (41%) with VCI-CSF profile.

⇨ **Baseline characteristics**

The population was composed of 49% of women, with a median age of 72.6

years, with a median of 10.3 years of education. The comparison of baseline

characteristics is shown in Table n° 4.

Table n°4: Baseline characteristics

	VCI-CSF	MD-CSF	*p*
Demographics			
Male gender	16 (52)	21 (47)	0.67
Median age [IQR]	71[64-78]	77 [68-80]	0.07
Median years of education [IQR]	9 [8-10]	11 [9-15]	**0.01**
Vascular risk factors			
HTN	22 (71)	32 (71)	0.10
DM	8 (26)	7 (16)	0.30
Dyslipidemia	20 (65)	23 (23)	0.25
Obesity	6 (19)	7 (16)	0.67
Tobacco	14 (45)	18 (40)	0.65
Heavy alcohol intake	13 (42)	5 (12)	**0.002**
Sleep apnea syndrome	9 (29)	5 (11)	**0.048**
Medical history			
Epilepsy [α]	1 (3)	0 (0)	NA
Atrial Fibrillation	2 (6)	6 (13)	0.46
PAD or coronaropathy	4 (13)	9 (20)	0.42
Ischemic stroke or TIA	7 (23)	4 (9)	0.11
Spontaneous ICH [α]	3 (10)	0 (0)	NA

Data are n (%); α: due to a lack of cases, a statistical analysis was not possible

IQR indicates interquartile range; HTN, arterial hypertension; DM, diabetes mellitus; PAD,
peripheral artery disease; TIA, transient ischemic attack; ICH, intracerebral hemorrhage; NA:
non assessable

Patients with MD-CSF tended to be older ($p = 0.07$), and to have significantly

higher level of education (median years of 11 vs 9, $p = 0.01$). Concerning the

vascular risk factors, HTN, DM and tobacco use were equally distributed in the two

groups.

Patients with VCI-CSF were more likely to present dyslipidemia (65% vs 23%), but that difference was not significant.

Heavy alcohol intake and sleep apnea syndrome were significantly more frequent in patients with VCI-CSF: respectively: 42 % vs 12 % (p= 0.002), and 29 % vs 11 % (p= 0.048).

⇨ **Neuropsychological data**

The median raw scores of the different tests and represented in Table n°5.

Table n° 5: Median raw scores to the different tests

|	VCI-CSF	MD-CSF	*p*
Cognitive screening tests			
MMSE (/30)	21 [17-24]	22 [16-25]	0.65
FAB (/18)	10 [7-14] [5]	14 [11-16] [7]	**0.003**
Test des 5 mots de Dubois (/10)	7 [5-8] [8]	7 [5-9] [11]	0.49
DRS			
Total (/144)	104 [91-121] [5]	119 [105-122] [8]	0.14
Attention (/37)	32 [29-35] [5]	33 [31-36] [10]	0.29
Initiation (/37)	23 [20-30] [5]	27 [21-31] [10]	0.26
Construction (/6)	6 [5-6] [6]	6 [6-6] [10]	0.09
Conceptualization (/39)	31 [28-36] [5]	37 [32-38] [10]	**0.007**
Memory (/25)	15 [12-17] [5]	14 [12-16] [10]	0.70
RL-RI 16			
RIm (/16)	11 [8-13] [8]	12 [10-13] [10]	0.89
RL1 (/16)	3 [2-4] [8]	4 [3-5] [10]	0.28
RT1 (/16)	9 [7-12] [8]	9 [7-12] [10]	0.84
Sensitivity to cueing (%)	55 [41-72] [9]	59 [33-69] [12]	0.67
VAT			
VAT Try 1 (/6)	2 [1-4] [2]	2 [1-4] [6]	0.77
VAT Try 1 + 2 (/12)	6 [3-9] [4]	6 [3-9] [6]	0.67
VAT delayed (/6)	4 [3-5] [11]	3 [2-6] [20]	0.77

Data are: median raw score (/ total) [IQR].The missing data are [X]

MMSE indicates Mini mental state evaluation; FAB, Frontal battery assessment; DRS, Dementia rating scale; RIm : immediate recall phase; RL1: first free recall phase score; RT1: first free + cued recall score, VAT: visual association test

The global cognitive efficiency, assessed with the MMSE and the DRS total scores did not differ in the two groups. The performances were approximately the same in verbal (RL-RI 16) and visual (VAT) memory testing between the two groups.

However there was a striking difference in executive functions: patients with VCI-CSF presented a FAB score significantly lower (10 [7-14] vs 14 [11-16], p = 0.003), as well as the conceptualization subscale score was significantly lower in the same category of patients (31 [28-36] vs 37 [32-38], p = 0.007).

Figure n° 3: Proportions of patients presenting pathologic scores at the different tests

DRS indicates dementia rating scale; VAT: visual association test

The figure n°3 represents the percentages of patients who presented pathologic scores in the neuropsychological testing (that is, under the 5th percentile for the DRS total score and its sub-scores, under the 10th percentile for the sensitivity to cueing). In our study the performances observed in neuropsychological test were mostly similar in the two groups. Only the proportion of pathologic scores at the DRS

conceptualization sub-score was significantly higher in patients with VCI –CSF (58% vs 25%, *p* = 0.0091).

Note: given a total of 97% pathologic scores at the DRS memory sub-score, this item was not include in the statistical analysis.

⇨ **MRI data**

1. Ischemic strokes and ICH

The numbers of large vessel ischemic strokes and ICH visualized on a 3T MRI evaluation are represented in the Table n°6.

Table n°6: Large vessel ischemic strokes and spontaneous ICH

	VCI-CSF	MD-CSF
Large vessel ischemic stroke		
MCA territory	2 (6)	3 (7)
PCA territory	3 (10)	1 (2)
PICA territory	1 (3)	3 (7)
Other PF arteries	2 (6)	1 (2)
Spontaneous ICH		
Supra tentorial, lobar	1 (3)	2 (4)
Supra tentorial, deep	2 (6)	0 (0)

Data are n (%). MCA indicates Middle cerebral artery; PCA, posterior cerebral artery; PICA, posterior inferior cerebellar artery; PF, posterior fossa; ICH, intracerebral hemorrhage

Due to a lack of cases, a statistical analysis could not be performed between the two groups. However, VCI-CSF patients presented more frequently infarctions in the PCA territory (10% vs 2%) and deep ICH (6 % vs 0%).

Note that none of our patients has presented any infarction in the ACA or of the AChoA territories, nor any posterior fossa hemorrhage. One patient presented a spontaneous intraventricular hemorrhage without parenchymal involvement (not represented in table n°6).

2. Small vessel diseases biomarkers

The repartition of small vessel diseases biomarkers in the two groups is represented in Table n°7.

Table n°7: Small vessel disease biomarkers

|	VCI-CSF	MD-CSF	*p*
Periventricular WMH			
Absent or mild	6 (19)	7 (16)	0.73
Moderate	14 (45)	18 (40)	
Severe	11 (36)	20 (44)	
Deep WMH			
Absent or mild	13 (42)	19 (42)	0.89
Moderate	13 (42)	17 (38)	
Severe	5 (16)	9 (20)	
Lacunes of presumed vascular origin			
Lobar [α]	0 (0)	1 (2)	NA
Deep	13 (42)	10 (22)	0.07
Mixed [α]	1 (3)	1 (2)	NA
Cerebral Microbleeds			
Lobar [α]	9 (29)	9 (20)	0.36
Deep	1 (3)	1 (2)	NA
Mixed [α]	3 (10)	3 (7)	NA
Cortical superficial siderosis [β]			
None	29 (94)	38 (84)	
Focal	1 (3)	2 (4)	0.30
Disseminated	1 (3)	5 (11)	

Data are n (%). WMH indicates white matter hyperintensities; NA, non assessable; α: due to a lack of cases, a statistical analysis was not possible; β : due to a lack of events, patient with focal and disseminated cortical superficial siderosis were regrouped to allow statistical analysis.

Severity of PVH and DWMH did not differ between the two groups. Likewise, the topographic distribution of CMB was approximately the same between the two groups. However, patient with VCI-CSF tend to present more frequently deep lacunes (42 % vs 22%, *p* = 0.07), and patients with MD-CSF tend to have more disseminated CSS (11% vs 3%, *p* = 0.30).

3. Strategic lesions

The repartition of strategic lesions in our study in represented in the figure n°4.

More than one third of patients with VCI-CSF presented at least one strategic vascular lesion: 9 (29 %) and 2 (6%) harbored respectively one and more than one lesion. In the other group, strategic lesions were slightly less frequent: 8 (18%) and 2 (4%) harbored respectively one and more than one lesion. However, that difference was non-significant ($p = 0.20$). Remark: due to a lack of events, patient presenting one and more than strategic lesion were regrouped to allow statistical analysis.

Figure n° 5: Examples of strategic vascular lesions in our cohort

- On the left: Cerebral T2 weighed MRI, axial plan passing through the basal ganglia. Note the bithalamic lacunar lesions and the EPVS in the head of caudate nuclei, the extensive periventricular WMH and the global cortico-subcortical atrophy that can fit in deep perforating vasculopathy. This patient aged 68 indeed presented multiple vascular risk factors.
- On the right: Cerebral MRI, axial FLAIR sequence, passing through the temporal horns of lateral ventricles. Note the hypersignal involving the right medial temporal lobe. This patient has presented a cerebral infarction in the superficial territory of the right posterior cerebral artery.

4. Pattern of cerebral atrophy

The pattern of cerebral atrophy in our study is represented in Table n°8.

Table n°8: Pattern of cerebral atrophy

|	VCI-CSF	MD-CSF	*p*
Median Evans' index [IQR]	0.31 [0.28-0.35]	0.29 [0.28- 0.32]	**0.01**
Left medial temporal atrophy [α][β]			
Absent or mild	1 (3)	0 (0)	
Moderate	15 (49)	25 (55)	0.66
Severe	15 (49)	19 (42)	
Right medial temporal atrophy [α][β]			
Absent or mild	2 (6)	2 (4)	
Moderate	21 (68)	23 (51)	0.12
Severe	8 (26)	19 (42)	
Left parietal atrophy			
Absent	8 (26)	5 (11)	
Mild	15 (48)	22 (49)	0.33
Moderate	5 (16)	11 (24)	
Severe	3 (10)	7 (16)	
Right parietal atrophy			
Absent	8 (26)	2 (4)	
Mild	14 (45)	21(47)	**0.04**
Moderate	5 (16)	14 (31)	
Severe	4 (13)	8 (18)	

Data are n (%); IQR indicates interquartile range; α = due to a lack of events, patient with absent or mild and moderate MTA were regrouped to allow statistical analysis; β = data were missing for one patient due to movement artefacts.

In our study, the Evan's index was significantly higher in patients with VCI-CSF

(0.31 [0.28-0.35] vs 0.29 [0.28- 0.32], *p* = 0.01).

The MTA did not differ between the two groups. However, the parietal atrophy

presented an asymmetric repartition: patients with MD-CSF were more likely to

harbor moderate (31% vs 16%) to severe (18% vs 13) right parietal atrophy ($p =$ 0.04). A similar pattern was observed with the left parietal atrophy but that difference was not significant ($p = 0.33$).

Figure n°6: Example of parietal atrophy in our study in our cohort

Cerebral MRI, T1- weighed, coronal slice passing through the occipital horns of lateral ventricles.

The parietal cortical atrophy is scored as moderate (grade 2 of the Koedam's classification) on the left and mild (grade 1) on the right. Note the apparent dilatation of posterior Cingulate sulci on the midline. Otherwise, we can observe diffuse periventricular hypointensities, correlating with white matter intensities on the FLAIR sequence (not shown).

⇨ **Focus on a specific etiology: the cerebral amyloid angiopathy.**

8 patients (10.5%) met the modified Boston criteria [62] for probable CAA which allows *in vivo* diagnosis of CAA. 5 presented the association of strictly lobar CMB and CSS, 2 the association of lobar ICH and CSS, 1 had lobar ICH + lobar CMB + CSS. Their radiological features and CSF profile are shown in Table n°7.

Table n°7: Patients of our cohort who fulfilled the criteria for probable CAA

Patient n°	Lobar ICH	Lobar CMB	CSS	CSF Profile
5	Yes	Yes	Yes	VCI
9	No	Yes	Yes	MD
15	Yes	No	Yes	MD
31	No	Yes	Yes	MD
51	No	Yes	Yes	VCI
61	Yes	No	Yes	MD
68	No	Yes	Yes	MD
71	No	Yes	Yes	MD

CSF indicates cerebro-spinal fluid; CMB: cerebral microbleeds; CSS: cortical superficial siderosis.

In this specific category of patients, 6 (75%) presented MD-CSF profile.

<u>Figure n°7: Examples of CAA patterns in our cohort</u>

- <u>On the left:</u> Cerebral MRI, T2 gradient echo-weighed sequence, axial slice passing through the frontal horns of lateral ventricles. Note the multiple CMB of strictly lobar, cortico-subcortical topography.
- <u>On the right:</u> Cerebral MRI, T2 gradient echo-weighed sequence, axial slice passing through the central sulcus. Note the lobar hemorrhage in the superior frontal gyrus, and the contralateral (focal) CSS.

DISCUSSION

In our study, patients with MD-CSF tended to be older (median age 77 [68-80] vs 71 [64-78] $p = 0.07$), which is congruent with current data in literature [34]. Patients with MD-CSF had better level of education (median years of education 11 [9-15] vs 9 [8-10], $p = 0.01$), which is discordant with the usual data, given that illiteracy or low educational achievement has been shown to be a robust risk factor for dementia of all types, but particularly of AD [63].

Concerning vascular risk factors, HTN, DM and tobacco use were equally distributed in the two groups. However, patients with VCI-CSF were significantly more likely to present heavy alcohol intake (42% vs 12%, $p = 0.002$), which is congruent with current data. In a nationwide retrospective cohort, Schwarzinger and al[64] highlighted that heavy alcohol intake was more frequently recorded in VaD than in other dementia types (11.2% vs 9.8%; $p < 0.0001$). Furthermore, heavy alcohol intake is a well-known risk factor of ICH occurrence [65]. Recently, in a cohort of ICH patients, alcohol-drinking habit has been shown to be an independent predictor of increased centrum *semi ovale* EPVS severity, suggesting that alcohol may influence the cerebral small vessel disease pattern [66].

Sleep apnea syndrome, was also more frequent in patients with VCI-CSF (29% vs 11%, $p = 0.048$) which is consistent with the higher risk of stroke associated with sleep apnea [67]. Moreover, in radiological studies patients with moderate to severe sleep apnea syndrome are more likely to harbor severe patterns of WMH [68].

The fact that patients with VCI-CSF did not present more history of stroke nor strategic lesions was unexpected, and might be attributed to the few number of patients.

Concerning neuropsychological data, the global cognitive efficiency did not differ between the two groups in our study. However patients with VCI-CSF had a significantly lower FAB score (10 [7-14] vs 14 [11-16], $p = 0.003$) and DRS conceptualization raw score (31 [28-36] vs 37 [32-38], $p = 0.007$). The same difference was confirmed after adjustment on age and level education: the proportion of patients with pathological DRS conceptualization scores was higher in patients

with VCI-CSF (58% vs 25%, *p* = 0.0091). Those results suggest that the executive functions are particularly altered in these patients.

However, we could not assess the precise nature of the deficit: due to the retrospective design and the differences in the neuropsychological evaluations, the executive and attentional functions were assessed with different tests. Systematic comparison was not allowed and the results of those tests were not included in our study. Thus, executive functions have been incompletely explored in our study. An extensive evaluation of executive functions may however be useful to precise the diagnosis. For example, Eckerström and *al* in a cohort of patient from the Gothenburg study shown that the word fluency F-A-S test and the Trail making test A best differentiated clinical AD from MD [69]. For further prospective cohorts, the use of batteries of test such as proposed by the GRECOG-Vasc committee [70] or the GREFEX [71], (which also encompasses behavioral evaluation) is mandatory.

In our study, the striking absence of difference between the two groups concerning the scores the memory tests (RL-RI 16 and VAT) may be related to the numerous missing data for those two tests, particularly in patients with MD-CSF.

Concerning radiological data, in our study, the topographic distribution of large vessel ischemic strokes, ICH and cerebral small vessel diseases biomarkers did not differ between the two groups.

However, patients who fulfilled the modified Boston criteria for CAA tend to present MD-CSF profile, which is expected given the strong association between CAA and AD, and congruent with recent data of the literature. Charidimou and *al* in their metanalysis [72] showed that patients with CAA specifically harbor lower $A\beta_1 42$ and $A\beta_1 40$ levels and higher t-Tau levels than normal control subjects, whereas no

difference in p-Tau levels was observed. There is a growing interest in the CSF profile of patients with CAA. Some authors even suggested that CSF analysis may help to diagnose preclinical CAA in patients fulfilling modified Boston Criteria for possible and probable CAA [73].

In our study, the Evan's index was significantly higher in patients with VCI-CSF (0.31 [0.28-0.35] vs 0.29 [0.28- 0.32], p = 0.01), reflecting that global cortical atrophy was more pronounced in this group. Such a result is striking, given patients with VCI-CSF tend to be younger than the others. To date, the diagnosis value of Evan's Index has not been specifically studied in VCI but patients with cerebrovascular disorders and especially those with subcortical vascular encephalopathy are likely to harbor subcortical global atrophy due to white matter lesions but also reduced cortical thickness attributed to secondary neuronal degeneration [9].

Even though a more pronounced MTA was expected in patient with MD-CSF, no difference was observed between are groups.

However, in our study, right parietal atrophy was more pronounced in patients with MD-CSF (p = 0.04) but similar in the two groups for the left parietal regions. Right focal variants of AD with right sighted asymmetry on neuroimaging have indeed been described, but in a recent review of literature, heterogeneity among the reports prevented a univocal description of this syndrome [74].

Our study has several strengths:

First of all, its clinical relevance: the differential diagnosis between VCI and mixed dementia is a clinical challenge for the clinician, as the natural history and the prognosis differs, and it is and an important issue for the patient, which may benefit

for a specific follow-up and symptomatic treatment (acetyl choline esterase inhibitors or memantin) in case of mixed dementia.

The contra-indication of lumbar puncture, particularly due to undergoing anticoagulants is a frequent situation in clinical practice. Consequently, we need to determine predictive factors for an underlying degenerative process.

Secondly, its originality: to date, there is no other study comparing neuropsychological performances, distribution of cerebrovascular lesions and pattern of atrophy specifically to the profile of CSF biomarkers.

Furthermore, we selected simple, easily available clinical data, validated and reproducible neuropsychological test, robust visual radiologic scales.

Positive emission tomography data were not included in our study, these exams being rarely present, moreover the aim of our study was to initially design a simple clinical score to supply the physician with simple available tools.

<u>However, our study has numerous limits.</u>

First of all, the limited number of patients, due to the rigorous criteria of inclusion to ensure a correct internal validity, limits the external validity.

Furthermore, ours is a tertiary center with a recruitment that concerns also rare forms of dementia as well as young patients, less likely to have mixed or vascular dementia.

Secondly, our study was based on a monocentric hospital-based cohort, in a tertiary center that recruited a heterogeneous population, including ultra-selected patients for follow-up or therapeutic protocols for AD.

Given the retrospective design of our study, we had significant missing data concerning of the neuropsychological tests that might prevented to highlight differences in mnesic profiles.

CONCLUSION

In our study, data suggest that patients with VCI are likely to harbor more pronounced deficits in executive functions, and that the pattern of atrophy may help to differentiate VCI from MD (global with VCI, posterior in MD). However, due to a small size population, we could not to establish a clinico-radiological score that may help the physician to differentiate patients with MD from those with VCI, inferred from their CSF profiles.

Large prospective cohorts with standardized neuropsychological batteries, especially those designed to assess executive functions, standardized reading plans of cerebral MRI with precise analysis of cerebral small vessel diseases biomarkers and pattern of atrophy are necessary to answer to this challenging diagnosis and clinically relevant question.

REFERENCES

1. Wortmann M. Dementia: a global health priority - highlights from an ADI and World Health Organization report. Alzheimers Res Ther. 2012; 4:40. doi: 10.1186/alzrt143.
2. Lobo A, Launer LJ, Fratiglioni L, et al. Prevalence of dementia and major subtypes in Europe: A collaborative study of population-based cohorts. Neurologic Diseases in the Elderly Research Group. Neurology 2000;54:4–9S.
3. Rockwood K, Wentzel C, Hachinski V, Hogan DB, MacKnight C, McDowell I. Prevalence and outcomes of vascular cognitive impairment. Vascular Cognitive Impairment Investigators of the Canadian Study of Health and Aging. *Neurology.* 2000;54(2):447-451. doi:10.1212/wnl.54.2.447
4. Mc Menemey,W.H.(1961)."The dementias and progressive diseases of the basal ganglia,"in *Neuropathology, 3rd Edn.*, edJ.G. Greenfield (London:E.Arnold), 475–521.
5. Leys D, Hénon H, Mackowiak-Cordoliani MA, Pasquier F. Post stroke dementia. *Lancet Neurol.* 2005;4(11):752-759. doi:10.1016/S1474-4422(05)70221-0
6. Pendlebury ST, Rothwell PM. Prevalence, incidence, and factors associated with pre-stroke and post-stroke dementia: a systematic review and meta-analysis. *Lancet Neurol.* 2009;8(11):1006-1018. doi:10.1016/S1474-4422(09)70236-4
7. Barbay M, Diouf M, Roussel M, Godefroy O; GRECOGVASC study group. Systematic Review and Meta-Analysis of Prevalence in Post-Stroke Neurocognitive Disorders in Hospital-Based Studies. Dement Geriatr Cogn Disord. 2018;46(5-6):322-334. doi:10.1159/000492920
8. Jellinger, K.A. The enigma of vascular cognitive disorder and vascular dementia. *ActaNeuropathol* 113**,**349–388 (2007).
9. Jellinger KA. Pathology and pathogenesis of vascular cognitive impairment-a critical update. *Front AgingNeurosci.* 2013;5:17. Published 2013 Apr 10. doi:10.3389/fnagi.2013.00017
10. Dichgans M, Leys D. Vascular Cognitive Impairment. *Circ Res.* 2017;120 (3):573-591. doi:10.1161/CIRCRESAHA.116.308426
11. Pasi M, Cordonnier C. Clinical Relevance of Cerebral Small Vessel Diseases. Stroke. 2020;51(1):47-53. doi:10.1161/STROKEAHA.119.024148
12. Pasi M, Boulouis G, Fotiadis P, et al. Distribution of lacunes in cerebral amyloid angiopathy and hypertensive small vessel disease. *Neurology.* 2017;88(23):2162-2168. doi:10.1212/WNL.0000000000004007
13. Chabriat H, Joutel A, Dichgans M, Tournier-Lasserve E, Bousser MG. Cadasil. *Lancet Neurol.* 2009;8(7):643-653. doi:10.1016/S1474-4422(09)70127-9
14. Moulin S, Labreuche J, Bombois S, Rossi C, Boulouis G, Hénon H,et al. Dementia risk after spontaneous intracerebral haemorrhage: a prospective cohort study. *Lancet Neurol*2016; 15:820–9.
15. Román GC, Tatemichi TK, Erkinjuntti T, et al. Vascular dementia: diagnostic criteria for research studies. Report of the NINDS-AIREN International Workshop. *Neurology.* 1993; 43(2):250-260. doi:10.1212/wnl.43.2.250
16. Hachinski V, Iadecola C, Petersen RC, et al. National Institute of Neurological Disorders and Stroke-Canadian Stroke Network vascular cognitive

impairment harmonization standards [published correction appears in Stroke. 2007 Mar; 38 (3):1118. Wallin, Anders [added]]. *Stroke*. 2006;37(9):2220-2241. doi:10.1161/01.STR.0000237236.88823.47

17. Sachdev P, Kalaria R, O'Brien J, et al. Diagnostic criteria for vascular cognitive disorders: a VASCOG statement. *Alzheimer Dis Assoc Disord*. 2014;28(3):206-218. doi:10.1097/WAD.0000000000000034

18. Looi JCL, Sachdev PS. Differentiation of vascular dementia from AD on neuropsychological tests. Neurology. 1999;53:670–678.

19. Albert MS, Dekosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7:270–279.

20. Kramer JH, Reed BR, Mungas D, Weiner MW, Chui HC. Executive dysfunction in subcortical ischaemic vascular disease. J Neurol Neurosurg Psychiatry. 2002;72(2):217-220. doi:10.1136/jnnp.72.2.217

21. Gupta M, Dasgupta A, Khwaja GA, Chowdhury D, Patidar Y, Batra A. The profile of behavioral and psychological symptoms in vascular cognitive impairment with and without dementia. Ann Indian Acad Neurol. 2013;16(4):599-602. doi:10.4103/0972-2327.120488

22. Meng XF, Yu JT, Wang HF, Tan MS, Wang C, Tan CC, Tan L (2014) Midlife vascular risk factors and the risk of Alzheimer's disease: a systematic review and meta-analysis. J Alzheimers Dis 42:1295–1310. doi:10.3233/JAD-140954

23. Biessels GJ, Staekenborg S, Brunner E, et al. Risk of dementia in diabetes mellitus: a systematic review. Lancet Neurol 2006; 5: 64–74.

24. Ott A, Breteler MM, de Bruyne MC, van Harskamp F, Grobbee DE, Hofman A (1997) Atrial fibrillation and dementia in a population-based study. The Rotterdam Study. Stroke 28:316–321

25. McCarron MO, Delong D, Alberts MJ (1999) APOE genotype as a risk factor for ischemic cerebrovascular disease: a meta-analysis. Neurology 53:1308–1311

26. de Leeuw FE, de Groot JC, Achten E, et al. Prevalence of cerebral white matter lesions in elderly people: a population based magnetic resonance imaging study. The Rotterdam Scan Study. J Neurol Neurosurg Psychiatry. 2001;70(1):9-14. doi:10.1136/jnnp.70.1.9

27. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348:1215–1222. doi: 10.1056/NEJMoa022066

28. Romero JR, Preis SR, Beiser A, DeCarli C, Viswanathan A, Martinez-Ramirez S, et al. Risk factors, stroke prevention treatments, and prevalence of cerebral microbleeds in the Framingham heart study. Stroke. 2014;45:1492–1494. doi: 10.1161/STROKEAHA.114.004130

29. Hénon H, Durieu I, Guerouaou D, Lebert F, Pasquier F, Leys D. Poststroke dementia: incidence and relationship to prestroke cognitive decline. Neurology. 2001;57(7):1216-1222. doi:10.1212/wnl.57.7.1216

30. Premkumar DR, Cohen DL, Hedera P, Friedland RP, Kalaria RN. Apolipoprotein E-epsilon4 alleles in cerebral amyloid angiopathy and cerebrovascular pathology associated with Alzheimer's disease. Am J Pathol. 1996;148(6):2083-2095.

31. Kalaria RN, Erkinjuntti T. Small vessel disease and subcortical vascular

dementia. J Clin Neurol. 2006;2(1):1-11. doi:10.3988/jcn.2006.2.1.1

32. Gold G, Giannakopoulos P, Montes-Paixao Júnior C, et al. Sensitivity and specificity of newly proposed clinical criteria for possible vascular dementia. *Neurology*. 1997;49(3):690-694. doi:10.1212/wnl.49.3.690

33. Schneider JA, Arvanitakis Z, Bang W, Bennett DA. Mixed brain pathologies account for most dementia cases in community-dwelling older persons. *Neurology*. 2007; 69:2197–2204. doi: 10.1212/01. wnl.0000271090.28148.24.

34. Bruandet A, Richard F, Bombois S, et al. Alzheimer disease with cerebrovascular disease and vascular dementia: clinical features and course compared with Alzheimer disease. J Neurol Neurosurg Psychiatry. 2009;80(2):133-139. doi:10.1136/jnnp.2007.137851

35. Korf ES, Wahlund LO, Visser PJ et al (2004) Medial temporal lobe atrophy on MRI predicts dementia in patients with mild cognitive impairment. Neurology 63:94–100

36. Laakso MP, Partanen K, Riekkinen P et al (1996) Hippocampal volumes in Alzheimer's disease, Parkinson's disease with and without dementia, and in vascular dementia: an MRI study. Neurology 46:678–681

37. Lehmann M, Rohrer JD, Clarkson MJ et al (2010) Reduced cortical thickness in the posterior cingulate gyrus is characteristic of both typical and atypical Alzheimer's disease. J Alzheimers Dis 20:587–598

38. Karas G, Scheltens P, Rombouts S et al (2007) Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. Neuroradiology 49:967–976

39. Kerrouche N, Herholz K, Mielke R, Holthoff V, Baron JC (2006) 18FDG PET in vascular dementia: Differentiation from Alzheimer's disease using voxel-based multivariate analysis. J Cereb Blood Flow Metab 26, 1213-1221

40. Thal DR, Beach TG, Zanette M, et al. [(18)F] flutemetamol amyloid positron emission tomography in preclinical and symptomatic Alzheimer's disease: specific detection of advanced phases of amyloid-β pathology. *AlzheimersDement*. 2015;11(8):975-985. doi:10.1016/j.jalz.2015.05.018

41. Marquié M, SiaoTick Chong M, Antón-Fernández A, et al. [F-18]-AV-1451 binding correlates with postmortem neurofibrillary tangle Braak staging. *Acta Neuropathol*. 2017;134(4):619-628. doi:10.1007/s00401-017-1740-8

42. Olsson B, Lautner R, Andreasson U, et al. CSF and blood biomarkers for the diagnosis of Alzheimer's disease: a systematic review and meta-analysis. Lancet Neurol. 2016;15(7):673-684. doi:10.1016/S1474-4422(16)00070-3

43. Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria [published correction appears in Lancet Neurol. 2014 Aug;13(8):757]. *Lancet Neurol.* 2014;13(6):614-629. doi:10.1016/S1474-4422(14)70090-0

44. Dumurgier J, Schraen S, Gabelle A, et al. Cerebrospinal fluid amyloid-β 42/40 ratio in clinical setting of memory centers: a multicentric study. *AlzheimersResTher*. 2015;7(1):30. Published 2015 Jun 1. doi:10.1186/s13195-015-0114-5

45. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):263-269.

doi:10.1016/j.jalz.2011.03.005

46. Folstein, M.F., Folstein, S.E., & McHugh, P.R. (1975). 'Mini-mental state'. A Practical method forgradinng the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12,189-198.

47. Dubois B, Slachevsky A, Litvan I, Pillon B. The FAB: a Frontal Assessment Battery at bedside. *Neurology.* 2000; 55(11):1621-1626. doi:10.1212/wnl.55.11.1621

48. B. Dubois, J. Touchon, F. Portet, et al.« Les 5 mots », épreuve simple et sensible pour le diagnostic de maladie d'Alzheimer. Presse Med, 31 (2002), pp. 1696-1699

49. Juva K, Sulkava R, Erkinjuntti T, Ylikoski R, Valvanne J, Tilvis R. Usefulness of the Clinical Dementia Rating scale in screening for dementia. Int Psychogeriatr. 1995;7(1):17-24. doi:10.1017/s1041610295001815

50. Grober, E., & Buschke, H. (1987). Genuine memory deficits in dementia. Developmental Psychology, 3, 13-36.

51. Van der Linden, M., Coyette, F., Poitrenaud, J., Kalafat, M., Calicis, F., Wyns, C., Membres du GREMEM. (2004). L'épreuve de rappel libre/rappel indicé à 16 items (RL/RI-16). In M. Van der Linden, S. Adam, A. Ag-niel, & Membres du GRENEM (Eds.), L'évaluation des troubles de la mémoire : présentation de quatre tests de mémoire épisodique avec leur étalonnage. (pp. 25-47). Marseille: Solal

52. Amieva, H. &Carcaillon, Laure & L'Alzit-Schuermans, P. & Millet, X. &Dartigues, J. &Fabrigoule, Colette. (2007). Test de rappel libre/rappel indicé à 16 items : normes en population générale chez des sujets âgés issues de l'étude des 3 Cités. Revue Neurologique - REV NEUROL. 163. 205-221. 10.1016/S0035-3787(07)90392-6.

53. Lindeboom J, Schmand B, Tulner L, Walstra G, Jonker C. Visual association test to detect early dementia of the Alzheimer type. J Neurol Neurosurg Psychiatry. 2002;73(2):126-133. doi:10.1136/jnnp.73.2.126

54. Pasi M, Marini S, Morotti A, et al. Cerebellar Hematoma Location: Implications for the Underlying Microangiopathy. *Stroke.* 2018;49(1):207-210. doi:10.1161/STROKEAHA.117.019286

55. Wardlaw JM, Smith EE, Biessels GJ, et al. Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. *Lancet Neurol.* 2013;12(8):822-838. doi:10.1016/S1474-4422(13)70124-8

56. Fazekas F, Chawluk JB, Alavi A, Hurtig HI, Zimmerman RA. MR signal abnormalities at 1.5 T in Alzheimer's dementia and normal aging. *AJR Am J Roentgenol.* 1987;149(2):351-356. doi:10.2214/ajr.149.2.351

57. Pasi M, Boulouis G, Fotiadis P, et al. Distribution of lacunes in cerebral amyloid angiopathy and hypertensive small vessel disease. *Neurology.* 2017;88(23):2162-2168. doi:10.1212/WNL.0000000000004007

58. Charidimou A, Linn J, Vernooij MW, et al. Cortical superficial siderosis: detection and clinical significance in cerebral amyloid angiopathy and related conditions. *Brain.* 2015;138(Pt 8):2126-2139. doi:10.1093/brain/awv162

59. Del Brutto OH, Mera RM, Zambrano M, Costa AF. The value of the Evans and bicaudate indices for predicting poor cognitive performance and central atrophy. Results from the Atahualpa Project. J Clin Neurosci. 2019;59:245-247. doi:10.1016/j.jocn.2018.08.024

60. Scheltens P, Leys D, Barkhof F, et al. Atrophy of medial temporal lobes on

MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates. *J NeurolNeurosurgPsychiatry*. 1992;55(10):967-972. doi:10.1136/jnnp.55.10.967

61. Koedam EL, Lehmann M, van der Flier WM, et al. Visual assessment of posterior atrophy development of a MRI rating scale. *EurRadiol*. 2011;21(12):2618-2625. doi:10.1007/s00330-011-2205-4

62. Greenberg S, Charidimou A. Diagnosis of cerebral amyloid angiopathy; evolution of the Boston criteria. *Stroke*. 2018; 49:00-00. DOI: 10.1161/STROKEAHA.117.016990.

63. Borenstein, Amy R PhD; Copenhaver, Cathleen I BS[*]; Mortimer, James A PhD[*] Early-Life Risk Factors for Alzheimer Disease, Alzheimer Disease & Associated Disorders: January-March 2006 - Volume 20 - Issue 1 - p 63-72 doi: 10.1097/01.wad.0000201854.62116.d7

64. Schwarzinger M, Pollock BG, Hasan OSM, Dufouil C, Rehm J; QalyDays Study Group. Contribution of alcohol use disorders to the burden of dementia in France 2008-13: a nationwide retrospective cohort study. Lancet Public Health. 2018;3(3):e124-e132. doi:10.1016/S2468-2667(18)30022-7

65. Ariesen MJ, Claus SP, Rinkel GJ, Algra A. Risk factors for intracerebral hemorrhage in the general population: a systematic review. Stroke 2003;34:2060 –2065

66. Wang X, Feng H, Wang Y, Zhou J, Zhao X. Enlarged Perivascular Spaces and Cerebral Small Vessel Disease in Spontaneous Intracerebral Hemorrhage Patients. Front Neurol. 2019;10:881. Published 2019 Aug 14. doi:10.3389/fneur.2019.00881

67. Culebras A, Anwar S. Sleep Apnea Is a Risk Factor for Stroke and Vascular Dementia. Curr Neurol Neurosci Rep. 2018;18(8):53. Published 2018 Jun 25. doi:10.1007/s11910-018-0855-1

68. Song TJ, Park JH, Choi KH, et al. Moderate-to-severe obstructive sleep apnea is associated with cerebral small vessel disease. Sleep Med. 2017;30:36-42. doi:10.1016/j.sleep.2016.03.006

69. Eckerström C, Eckerström M, Göthlin M, et al. Characteristic Biomarker and Cognitive Profile in Incipient Mixed Dementia. J Alzheimers Dis. 2020;73(2):597-607. doi:10.3233/JAD-190651

70. Godefroy O, Leclercq C, Roussel M, et al. French adaptation of the vascular cognitive impairment harmonization standards: the GRECOG-VASC study. Int J Stroke. 2012;7(4):362-363. doi:10.1111/j.1747-4949.2012.00794.x

71. Roussel M, Martinaud O, Hénon H, et al. The Behavioral and Cognitive Executive Disorders of Stroke: The GREFEX Study. PLoS One. 2016; 11(1):e0147602. Published 2016 Jan 29. doi:10.1371/journal.pone.0147602

72. Charidimou A, Friedrich JO, Greenberg SM, Viswanathan A. Core cerebrospinal fluid biomarker profile in cerebral amyloid angiopathy: A meta-analysis. Neurology. 2018;90(9):e754-e762. doi:10.1212/WNL.0000000000005030

73. van Etten ES, Verbeek MM, van der Grond J, et al. β-Amyloid in CSF: Biomarker for preclinical cerebral amyloid angiopathy. Neurology. 2017;88(2):169-176. doi:10.1212/WNL.0000000000003486

74. Abbate C, Trimarchi PD, Inglese S, et al. Does the Right Focal Variant of Alzheimer's Disease Really Exist? A Literature Analysis. J Alzheimers Dis. 2019;71(2):405-420. doi:10.3233/JAD-190338

SUPPLEMENTAL MATERIALS

Supplemental material n°1: STRIVE consensus criteria by Wardlaw and *al* [(55)]

	Recent small subcortical infarct	White matter hyperintensity	Lacune	Perivascular space	Cerebral microbleed
Example image					
Schematic	DWI	FLAIR	FLAIR	T1/FLAIR	T2*/SWI
Usual diameter	≤20 mm	Variable	3–15 mm	≤2 mm	≤10 mm
Comment	Best identified on DWI	Located in white matter	Usually have hyperintense rim	Most linear without hyperintense rim	Detected on GRE seq., round or ovoid, blooming
DWI	↑	↔	↔/(↓)	↔	↔
FLAIR	↑	↑	↓	↓	↔
T2	↑	↑	↑	↑	↔
T1	↓	↔/(↓)	↓	↓	↔
T2*-weighted GRE	↔	↑	↔ (↓ if haemorrhage)	↔	↓↓

↑ Increased signal   ↓ Decreased signal   ↔ Iso-intense signal

This diagram represent the consensus criteria for MRI pattern of cerebral small vessel diseases biomarkers, according to the several sequences.

DWI indicates Diffusion weighed images; GRE: Gradient Echo; FLAIR: Fluid Attenuation Inversion Recovery

PRE indicates precuneus; PCS, posterior cingulate sulcus; PAR, parietal cortex

In sagittal, axial and coronal orientation, this rating scale rates 0 = no atrophy, 1 = minimal atrophy, 2 = moderate atrophy and 3 = severe atrophy.

  - ➤ In sagittal orientation, widening of posterior cingulate- and parieto-occipital sulcus and atrophy of the precuneus was evaluated.
  - ➤ In axial orientation, the widening of the posterior cingulate sulcus and sulcal dilatation in the parietal lobes was evaluated.
  - ➤ In coronal orientation, the widening of the posterior cingulate sulcus and sulcal dilatation in the parietal lobes was evaluated.

AUTEUR :	Nom : WITTWER	Prénom : Aymeric

Date de soutenance : le mercredi 23 septembre 2020
Titre de la thèse : Facteurs prédictifs de pathologie Alzheimer, inférée d'après le profil des biomarqueurs du liquide cérébro-spinal, chez des patients porteurs de troubles neurocognitifs vasculaires au centre mémoire de Lille.

Thèse - Médecine - Lille 2020
Cadre de classement : Neurologie
DES + spécialité : Neurologie
Mots-clés : Troubles neurocognitifs vasculaires, Biomarqueurs, Alzheimer

Résumé :
Contexte : Les troubles neurocognitifs vasculaires (TNCV) représentent la deuxième cause de démence après la maladie d'Alzheimer (MA), à laquelle ils s'associent fréquemment, formant les démences mixtes (DM). En France, en 2020, le clinicien s'appuie sur les biomarqueurs du liquide cérébro-spinal (LCS) pour documenter le diagnostic *in vivo* de MA probable dans sa pratique clinique. Cependant, la ponction lombaire n'est pas toujours disponible, et peut être contre-indiquée par la prise d'antithrombotiques, fréquente dans cette population. L'objectif principal de notre étude est d'identifier chez les patients porteurs de TNCV, les facteurs cliniques, neuropsychologiques et d'imagerie prédictifs d'une MA associée inférée d'après les biomarqueurs du LCS.

Patients et méthodes : Dans une cohorte monocentrique du centre mémoire de Lille, nous avons inclus les patients dont le dernier diagnostic retenu était celui de TCNV ou de DM, et pour lesquels les biomarqueurs du LCS étaient disponibles. Nous avons alors défini 2 profils de LCS selon lesquels étaient répartis les patients: TNCV-LCS et DM-LCS. Nous avons alors comparé en analyse bivariée les caractéristiques cliniques, neuropsychologiques et d'imagerie par IRM (avec une analyse rigoureuse des marqueurs de maladies cérébrovasculaires et du pattern d'atrophie cérébrale) en fonction du profil du LCS.

Résultats : 76 patients ont été inclus, dont 45 (59 %) avec un profil MD-LCS et 31 (41%) un profil TNCV-LCS. Les patients de profil TCNV-LCS présentaient des scores bruts significativement plus bas à la Batterie Rapide d'Efficience Frontale (p = 0.003). De même, ces patients présentaient une plus grande proportion de scores déficitaires à l'épreuve des concepts de l'échelle de démence de Mattis (p = 0.0091). La répartition des marqueurs de maladies cérébrovasculaires ne différait pas entre les 2 groupes. Les patients de profil TCNV-LCS présentaient une atrophie cérébrale globale plus sévère (p = 0.01) tandis que ceux de profil DM-LCS présentaient une atrophie pariétale plus marquée, significative à droite (p = 0.04) mais pas à gauche.

Conclusion : Nos résultats suggèrent que les sujets porteurs de TNCV présentent des troubles dysexécutifs plus marqués que ceux porteurs de DM, et que le pattern d'atrophie cérébrale diffère entre ces 2 pathologies. Des études de cohorte prospectives comportant des batteries de tests neuropsychologiques et des plans d'analyse de l'IRM cérébrale standardisées apparaissent nécessaires pour répondre à cet enjeu diagnostique et thérapeutique. Une perspective prometteuse serait d'établir un score clinico-radiologique prédictif du profil de LCS et permettant donc de s'en affranchir lorsque le prélèvement n'est pas possible.

Composition du Jury :

Présidente: Mme le Professeur Florence PASQUIER

Assesseurs: Mme le Professeur Charlotte CORDONNIER, M. le Docteur Gregory KUCHCINSKI
Directrice de thèse: Mme le Docteur Marie-Anne MACKOWIAK-CORDOLIANI